PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

0 reported adverse events

Drug classes: Endoglycosidase [EPC] Programmed Death Receptor-1 Blocking Antibody [EPC]

These side effects are most commonly reported by patients taking PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH:

# Side effect Count
See all common reactions for PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
See all enriched reactions for PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH